Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated Advanced/Metastatic NSCLC
NCT06671379Phase 3Active, not recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ruzaltatug rezetecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoint: Progression-Free Survival at 32 months. Started Nov 2024; status: active, not recruiting.
02
Drugs
ruzaltatug rezetecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06671379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671379.